Skip to content
Triangle logo TriangleGet started
← Study library

NCT00534118 · REGISTRY CONDITION SEARCH

Donor Lymphocyte Infusion in Treating Patients With Recurrent or Persistent Hematologic Cancer After Donor Stem Cell Transplant

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
NA
Status at capture
COMPLETED
Registry last update
2020-08-26

RATIONALE: Giving an infusion of donor lymphocytes may be able to kill cancer cells in patients with hematologic cancer that has come back after a donor stem cell transplant. PURPOSE: This clinical trial is studying how well donor lymphocyte infusion works in treating patients with recurrent or persistent hematologic cancer after donor stem cell transplant.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Complete Remission Rate

→

outcome · POSTED

Duration of Complete Response in Months (Maximum 12)

→

outcome · POSTED

Acute Graft-versus-host Disease

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
DISEASE CHARACTERISTICS: * Has undergone allogeneic stem cell transplantation (ASCT) for hematologic malignancy at least 30 days ago * No failure to engraft following transplant * No active acute or chronic graft-versus-host disease (GVHD) * Minimal GVHD allowed * Persistent or relapsed disease after ASCT, including 1 of the following: * Chronic myelogenous leukemia (CML), meeting any of the following criteria: * Molecular relapse (may be treated with imatinib mesylate after transplant), as defined by any of the following: * ASCT was non-T-cell depleted, a negative bcr/abl was documented by PCR post-transplant, and bcr/abl is now detectable by 2 consecutive PCR determinations \> 30 days apart * ASCT was non-T-cell depleted and bcr/abl is detectable by PCR at any time after day 180 post-transplant * Cytogenetic relapse after 3-6 months of imatinib mesylate * Relapsed chronic phase, accelerated phase, or blastic phase CML after 3-6 months of imatinib mesylate * Must currently be in chronic phase or accelerated phase CML only * Patients with blastic phase CML must attain a second chronic phase * Acute myeloid leukemia, acute lymphoblastic leukemia, or myelodysplastic syndromes, meeting any of the following criteria: * Molecular relapse, as evidenced by \< 5% blasts in the bone marrow and the patient's leukemia-specific molecular abnormality detectable by PCR * Cytogenetic relapse, as evidenced by \< 5% blasts in the bone marrow and the patient's leukemia-specific chromosome abnormality detectable by standard cytogenetics at any time after day 60 post-transplant * Hematologic relapse, as evidenced by \> 20% blasts in bone marrow or soft tissue recurrence * Must be treated with chemotherapy after transplant, but before study donor lymphocyte infusion (DLI) * Multiple myeloma * Relapsed disease or recurrence of M-protein after thalidomide or other salvage treatment * Prior post-transplant documentation of disappearance of M-protein by immunofixation * Residual or progressive disease * Rising M-protein level at any time post-transplant (measured at 3-month intervals) * Original M-protein detectable at 6 months post-transplant * Immune protein electrophoresis (IPEP) is required to show that M-component is the same on day 60 post-transplant as pre-transplant * Residual (\> 5%) plasma cells in bone marrow * Relapsed non-Hodgkin lymphoma or Hodgkin lymphoma * Relapse or progression of disease must be evidenced within 3 months prior to donor lymphocyte infusion by physical exam, radiographic studies, or molecular studies * Tumor should be re-biopsied to determine histology * If Epstein-Barr virus (EBV) lymphoma is suspected, peripheral blood must be assayed for EBV genome (i.e., EBV DNA testing by PCR) within the past 30 days * EBV infection with associated pancytopenia * Persistent or refractory pancytopenia with EBV genome detected by PCR in the peripheral blood * Refractory pancytopenia is defined as pancytopenia that is poorly responsive to growth factors and/or transfusions * EBV lymphoproliferative disorder * Clonal lymphadenopathy that is refractory to standard therapy with acyclovir and immunoglobulin (DLI may be given with rituximab) * Not a candidate for repeat ASCT * Chimerism status is not required for determining eligibility for DLI * Patients eligible for allogeneic ASCT, but for whom DLI is offered as the first option, should have full donor chimerism at relapse or after therapy for relapsed disease * Patients with relapsed underlying disease after transplant who achieved remission after chemotherapy are allowed * No CNS recurrence that is not cleared by standard chemotherapy * CNS remission status must be maintained for 2 weeks * Original hematopoietic progenitor stem cell donor must be available for cell donation * No syngeneic donors PATIENT CHARACTERISTICS: * Karnofsky performance status 60-100% * Life expectancy ≥ 8 weeks * Creatinine \< 3 mg/dL * ABO/Rh and CMV IgG/IgM status known * No HIV1 and HIV2 antibody * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during and for 3 months (males) or 6 months (females) after completion of study treatment PRIOR CONCURRENT THERAPY: * See Disease Characteristics
healthy Volunteers
false
maximum Age
76 Years
sex
ALL
std Ages
  1. CHILD
  2. ADULT
  3. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Patients receive up to four donor lymphocyte infusions at least 1 month apart in the absence of disease progression, unacceptable toxicity, or uncontrolled graft-versus-host disease
    intervention Names
    1. Biological: donor lymphocytes
    label
    Infusion
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Infusion
    description
    Given IV
    name
    donor lymphocytes
    type
    BIOLOGICAL
Study design
allocation
NA
intervention Model
SINGLE_GROUP
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
39
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    continued or induced complete remission after DLI
    measure
    Complete Remission Rate
    time Frame
    100 days post DLI
  2. description
    For participants who achieve a complete remission after DLI, the duration of time until 1) relapse or 2) death in remission or 3) subsequent DLI or 4) last followup (at 1 year after DLI)
    measure
    Duration of Complete Response in Months (Maximum 12)
    time Frame
    1 year post DLI
secondary Outcomes
  1. description
    development of grade III-IV acute graft-versus-host disease (GVHD) per Glucksberg criteria
    measure
    Acute Graft-versus-host Disease
    time Frame
    100 days post DLI
Full study description
brief Summary
RATIONALE: Giving an infusion of donor lymphocytes may be able to kill cancer cells in patients with hematologic cancer that has come back after a donor stem cell transplant. PURPOSE: This clinical trial is studying how well donor lymphocyte infusion works in treating patients with recurrent or persistent hematologic cancer after donor stem cell transplant.
detailed Description
OBJECTIVES: Primary * Determine if the complete response rate exceeds 10% in patients with recurrent or persistent hematologic malignancies treated with donor lymphocyte infusion. Secondary * Estimate the complete response rate in these patients. * Assess the toxicity of donor lymphocyte infusion in these patients. OUTLINE: Patients receive up to four donor lymphocyte infusions at least 1 month apart in the absence of disease progression, unacceptable toxicity, or uncontrolled graft-versus-host disease.
Source references
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-6a28a15822e752fe7e65
      requested nct id
      NCT00534118
      primary nct id
      NCT00534118
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      payload sha256
      e6c452b0e26344a1df5d3c8b39c92f5e99191bff2e5164293e6e0702a1d75f19
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-6a28a15822e752fe7e65
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT00534118
      occurrences
      1. context exact
        NCT00534118
        end
        11
        exact text
        NCT00534118
        start
        0
      offset unit
      unicode_code_points
      query cond
      Plasma Cell Neoplasms
      query disease state id
      ds-plasma-cell-neoplasms
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      source json pointer
      /studies/625/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      6c47699ff14a8346492eeaaf930ace62888a5ebfbeadf210c3938eab2fad155b
    2. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-80ec5182a83aeae9c8ae
      requested nct id
      NCT00534118
      primary nct id
      NCT00534118
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      a4be8fb2a7db9247bdfed231ef84ae19b3babbe8d619ebf7403cceb730eae2d4
      payload sha256
      058e079496b73bc0de071934afc2cc8ab085f009ab816eadcd2709a4752dd658
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-80ec5182a83aeae9c8ae
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT00534118
      occurrences
      1. context exact
        NCT00534118
        end
        11
        exact text
        NCT00534118
        start
        0
      offset unit
      unicode_code_points
      query cond
      Childhood Myelodysplastic Neoplasms
      query disease state id
      ds-myelodysplastic-neoplasms-pediatric
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-childhood-myelodysplastic-neoplasms-000.json
      source file sha256
      a4be8fb2a7db9247bdfed231ef84ae19b3babbe8d619ebf7403cceb730eae2d4
      source json pointer
      /studies/40/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      6c47699ff14a8346492eeaaf930ace62888a5ebfbeadf210c3938eab2fad155b
    3. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-8f92dd99bb6d282111ed
      requested nct id
      NCT00534118
      primary nct id
      NCT00534118
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      193739e64f77123de4344901c9970a0996a667fa587f14135380bef3ae38e11d
      payload sha256
      03bde7df6ed2ff0be815bd1c2c3c235c0893fc06b0bb70ebf185224c53eee49c
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-8f92dd99bb6d282111ed
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT00534118
      occurrences
      1. context exact
        NCT00534118
        end
        11
        exact text
        NCT00534118
        start
        0
      offset unit
      unicode_code_points
      query cond
      Childhood Chronic Myeloid Leukemia
      query disease state id
      ds-chronic-myeloid-leukemia-pediatric
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-childhood-chronic-myeloid-leukemia-000.json
      source file sha256
      193739e64f77123de4344901c9970a0996a667fa587f14135380bef3ae38e11d
      source json pointer
      /studies/36/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      6c47699ff14a8346492eeaaf930ace62888a5ebfbeadf210c3938eab2fad155b

    Preserved source evidence · Not medical advice